Currently, squamous cell carcinoma antigen (SCC-Ag), carbohydrate antigen 19-9 (CA 19-9), and carcinoembryonic antigen (CEA) are commonly used to assess treatment response in patients with cervical cancer. This evidence concerns the gene CEACAM5 and cervical carcinoma.